
Giovanni Tallini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7235246/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. Journal of Clinical Pathology, 2023, 76, 47-52.	1.0	9
2	Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of <i>PIK3CA</i> mutations. Journal of Clinical Pathology, 2022, 75, 488-492.	1.0	4
3	Primary highâ€grade nonâ€anaplastic thyroid carcinoma: a retrospective study of 364 cases. Histopathology, 2022, 80, 322-337.	1.6	41
4	TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study. Journal of Clinical Pathology, 2022, 75, 416-421.	1.0	6
5	International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. Journal of Clinical Oncology, 2022, 40, 96-104.	0.8	57
6	Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I integrity with oncocytic tumors. Journal of Pathology: Clinical Research, 2022, 8, 155-168.	1.3	10
7	Mutational landscape in squamous cell carcinoma of the nail unit. Experimental Dermatology, 2022, 31, 854-861.	1.4	4
8	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2022, 169, 103567.	2.0	26
9	Relevance of ARID1A Mutations in Endometrial Carcinomas. Diagnostics, 2022, 12, 592.	1.3	6
10	Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology, 2022, 33, 27-63.	5.2	388
11	Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene Panel. Diagnostics, 2022, 12, 1058.	1.3	4
12	BRAF and MLH1 Analysis Algorithm for the Evaluation of Lynch Syndrome Risk in Colorectal Carcinoma Patients: Evidence-Based Data from the Analysis of 100 Consecutive Cases. Journal of Molecular Pathology, 2022, 3, 115-124.	0.5	1
13	Proposal of a molecular testing algorithm for differentiated thyroid cancer (DTC) Journal of Clinical Oncology, 2022, 40, e18090-e18090.	0.8	0
14	Correlation of molecular alterations with pathological features in hepatocellular carcinoma: Literature review and experience of an Italian center. World Journal of Gastroenterology, 2022, 28, 2854-2866.	1.4	4
15	Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients. Thyroid, 2021, 31, 264-271.	2.4	40
16	Predictive molecular pathology in the time of coronavirus disease (COVID-19) in Europe. Journal of Clinical Pathology, 2021, 74, 391-395.	1.0	17
17	Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 265-281.	1.4	25
18	Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 62-72.	1.1	20

#	Article	IF	CITATIONS
19	Oncocytic Carcinoma, Thyroid. Encyclopedia of Pathology, 2021, , 1-7.	0.0	о
20	Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP). Encyclopedia of Pathology, 2021, , 1-7.	0.0	0
21	Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?. Endocrine Pathology, 2021, 32, 63-76.	5.2	55
22	Gene expression profile in metastatic and non-metastatic parathyroid carcinoma. Endocrine-Related Cancer, 2021, 28, 111-134.	1.6	14
23	ARID1A and CTNNB1/β-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular Classification. Cancers, 2021, 13, 950.	1.7	31
24	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. Diagnostics, 2021, 11, 342.	1.3	15
25	Different Methods in HPV Genotyping of Anogenital and Oropharyngeal Lesions: Comparison between VisionArray® Technology, Next Generation Sequencing, and Hybrid Capture Assay. Journal of Molecular Pathology, 2021, 2, 29-41.	0.5	0
26	What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors. Diagnostics, 2021, 11, 697.	1.3	57
27	IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. Pathology Research and Practice, 2021, 221, 153445.	1.0	6
28	The clinical and prognostic role of ALK in glioblastoma. Pathology Research and Practice, 2021, 221, 153447.	1.0	5
29	Molecular alterations in pancreatic tumors. World Journal of Gastroenterology, 2021, 27, 2710-2726.	1.4	16
30	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. Pathologica, 2021, 113, 262-271.	1.3	13
31	Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4). Thyroid, 2021, 31, 1814-1821.	2.4	15
32	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. Critical Reviews in Oncology/Hematology, 2021, 165, 103436.	2.0	40
33	Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion byÂFISH. Journal of Molecular Diagnostics, 2021, 23, 1185-1194.	1.2	7
34	Identification of miR-499a-5p as a Potential Novel Biomarker for Risk Stratification in Endometrial Cancer. Frontiers in Oncology, 2021, 11, 757678.	1.3	9
35	Unexpected Widespread Bone Metastases from a BRAF K601N Mutated Follicular Thyroid Carcinoma within a Previously Resected Multinodular Goiter. Endocrine Pathology, 2021, , .	5.2	1
36	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. Frontiers in Oncology, 2021, 11, 778461.	1.3	4

#	Article	IF	CITATIONS
37	Diagnostic challenges of an incidental finding: case report of definitely-congenital glioblastoma multiforme in a very preterm infant. Italian Journal of Pediatrics, 2021, 47, 234.	1.0	1
38	What Is New in Thyroid Cancer: The Special Issue of the Journal Cancers. Cancers, 2020, 12, 3036.	1.7	3
39	Cytokine storm in aged people with CoV-2: possible role of vitamins as therapy or preventive strategy. Aging Clinical and Experimental Research, 2020, 32, 2115-2131.	1.4	50
40	Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. Molecular Biology Reports, 2020, 47, 8235-8241.	1.0	2
41	miR-196B-5P and miR-200B-3P Are Differentially Expressed in Medulloblastomas of Adults and Children. Diagnostics, 2020, 10, 265.	1.3	6
42	BRAF Exon 15 Mutations in Papillary Carcinoma and Adjacent Thyroid Parenchyma: A Search for the Early Molecular Events Associated with Tumor Development. Cancers, 2020, 12, 430.	1.7	8
43	Does the Site of Origin of the Microcarcinoma with Respect to the Thyroid Surface Matter? A Multicenter Pathologic and Clinical Study for Risk Stratification. Cancers, 2020, 12, 246.	1.7	15
44	Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel. Diagnostics, 2020, 10, 250.	1.3	39
45	Adequacy of endosonographyâ€derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer. Clinical Respiratory Journal, 2019, 13, 590-597.	0.6	4
46	A rare case of intracranial extra-axial ependymoma. Ultrastructural Pathology, 2019, 43, 216-219.	0.4	0
47	How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid, 2019, 29, 1792-1803.	2.4	33
48	Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features. Endocrine, 2019, 64, 97-108.	1.1	35
49	Concordance, intra- and inter-observer agreements between light microscopy and whole slide imaging for samples acquired by EUS in pancreatic solid lesions. Digestive and Liver Disease, 2019, 51, 1574-1579.	0.4	4
50	BRAF V600E Status and Stimulated Thyroglobulin at Ablation Time Increase Prognostic Value of American Thyroid Association Classification Systems for Persistent Disease in Differentiated Thyroid Carcinoma. International Journal of Endocrinology, 2019, 2019, 1-7.	0.6	0
51	What's New in Thyroid Tumor Classification, the 2017 World Health Organization Classification of Tumours of Endocrine Organs. , 2019, , 37-47.		1
52	Consistency and reproducibility of nextâ€generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathology, 2019, 127, 285-296.	1.4	39
53	Invited review—next-generation sequencing: a modern tool in cytopathology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 3-11.	1.4	31
54	Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements Journal of Clinical Oncology, 2019, 37, 2028-2028.	0.8	19

#	Article	IF	CITATIONS
55	Effect of grade on survival in IDH-mutant grade II and grade III gliomas Journal of Clinical Oncology, 2019, 37, 2036-2036.	0.8	0
56	IDH1 polymorphism G105G (rs11554137) as a prognostic factor in gliomas Journal of Clinical Oncology, 2019, 37, e14734-e14734.	0.8	0
57	The Role of Next-Generation Sequencing in the Cytologic Diagnosis of Pancreatic Lesions. Archives of Pathology and Laboratory Medicine, 2018, 142, 458-464.	1.2	28
58	Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1105GGT) in brain tumors of a cohort of Italian patients. Scientific Reports, 2018, 8, 4459.	1.6	9
59	Clival chordomas: considerations after 16 years of endoscopic endonasal surgery. Journal of Neurosurgery, 2018, 128, 329-338.	0.9	72
60	Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists. Modern Pathology, 2018, 31, 39-55.	2.9	107
61	Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance. Histopathology, 2018, 72, 6-31.	1.6	94
62	Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Cancer Biomarkers, 2018, 21, 323-334.	0.8	37
63	Role of microRNAs in the main molecular pathways of hepatocellular carcinoma. World Journal of Gastroenterology, 2018, 24, 2647-2660.	1.4	66
64	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. Future Oncology, 2018, 14, 1559-1567.	1.1	17
65	Temozolomide rechallenge in recurrent glioblastoma: when is it useful?. Future Oncology, 2018, 14, 1063-1069.	1.1	11
66	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Modern Pathology, 2018, 31, 1770-1786.	2.9	739
67	Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?. Endocrine, 2018, 59, 143-150.	1.1	57
68	Not the same thing: metastatic PTCs have a different background than ATCs. Endocrine Connections, 2018, 7, 1370-1379.	0.8	14
69	Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas. Oncotarget, 2018, 9, 1813-1825.	0.8	30
70	Third-line therapy in glioblastoma: Analysis of a single centre database Journal of Clinical Oncology, 2018, 36, e14057-e14057.	0.8	0
71	Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid, 2017, 27, 512-517.	2.4	109
72	Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma. Clinical Lung Cancer, 2017, 18, e215-e217.	1.1	5

#	Article	IF	CITATIONS
73	Role of <i>MGMT</i> Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. Oncologist, 2017, 22, 432-437.	1.9	61
74	Team work and cytopathology molecular diagnosis of solid pancreatic lesions. Digestive Endoscopy, 2017, 29, 657-666.	1.3	13
75	Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. Journal of Neuro-Oncology, 2017, 135, 245-254.	1.4	17
76	Relationship among clinical, pathological and bio-molecular features in low-grade epilepsy-associated neuroepithelial tumors. Journal of Clinical Neuroscience, 2017, 44, 158-163.	0.8	15
77	The History of the Follicular Variant of Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 15-22.	1.8	107
78	The role of clinical characteristics in low grade gliomas in molecular era. Annals of Oncology, 2017, 28, v115.	0.6	0
79	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	1.4	58
80	The role of treatments in IDH mutant molecular astrocytomas. Annals of Oncology, 2017, 28, vi76.	0.6	1
81	Prognostic factors for IDH mutant molecular astrocytomas. Annals of Oncology, 2017, 28, v111.	0.6	Ο
82	The role of clinical and molecular characteristics in low grade gliomas. Annals of Oncology, 2017, 28, vi75-vi76.	0.6	0
83	Low grade glioma patients with IDH mutation and 1p19q codeletion: To treat or not to treat?. Journal of Clinical Oncology, 2017, 35, 2017-2017.	0.8	6
84	The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma. PLoS ONE, 2017, 12, e0177822.	1.1	5
85	Molecular analysis driven video-assisted thoracic surgery resections in bilateral synchronous lung cancers: from the test tube to the operatory room. Annals of Translational Medicine, 2017, 5, 397-397.	0.7	1
86	ACTR-01. THE ROLE OF CLINICAL CHARACTERISTICS IN LOW GRADE GLIOMAS PATIENTS IN THE ERA OF MOLECULAR BIOMARKERS: AÂSTUDY FROM GRUPPO ITALIANO COOPERATIVO DI NEURO-ONCOLOGIA (GICNO). Neuro-Oncology, 2016, 18, vi1-vi1.	0.6	0
87	Search for HBV and HCV Genome in Cancer Cells of Pancreatic Tumors. Pancreas, 2016, 45, e12-e14.	0.5	6
88	<i>NTRK</i> fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer, 2016, 122, 1097-1107.	2.0	195
89	Postoperative outcome of body core temperature rhythm and sleep-wake cycle in third ventricle craniopharyngiomas. Neurosurgical Focus, 2016, 41, E12.	1.0	22
90	Cytological features of "noninvasive follicular thyroid neoplasm with papillary-like nuclear features―and their correlation with tumor histology. Human Pathology, 2016, 54, 134-142.	1.1	190

#	Article	IF	CITATIONS
91	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. JAMA Oncology, 2016, 2, 1023.	3.4	1,192
92	RET mutation and increased angiogenesis in medullary thyroid carcinomas. Endocrine-Related Cancer, 2016, 23, 665-676.	1.6	24
93	Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine-needle aspirates. Journal of Clinical Pathology, 2016, 69, 986-991.	1.0	28
94	Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review. Endocrine Pathology, 2016, 27, 55-64.	5.2	52
95	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 264-274.	1.8	179
96	Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers. Endocrine, 2016, 53, 145-156.	1.1	16
97	Sarcomas and Related Mesenchymal Tumors. , 2016, , 487-506.		0
98	Fully automated PCR detection of KRAS mutations on pancreatic endoscopic ultrasound fine needle aspirates Journal of Clinical Oncology, 2016, 34, e15726-e15726.	0.8	0
99	Hepatitis B Virus Infection and Pancreatic Neuroendocrine Tumor. Pancreas, 2015, 44, 341-342.	0.5	2
100	Randomized Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration With and Without Rapid On-site Evaluation for Lung Cancer Genotyping. Chest, 2015, 148, 1430-1437.	0.4	126
101	Anaplastic Thyroid Carcinoma: Molecular Tools for Diagnosis and Therapy. International Journal of Endocrinology, 2015, 2015, 1-2.	0.6	3
102	New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. Critical Reviews in Oncology/Hematology, 2015, 94, 348-359.	2.0	43
103	Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells. Pituitary, 2015, 18, 905-911.	1.6	31
104	KRAS Mutant Allele-Specific Imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. Journal of Clinical Pathology, 2015, 68, 265-269.	1.0	13
105	Ectopic Thyroid Tissue in the Adrenal Gland. International Journal of Surgical Pathology, 2015, 23, 170-175.	0.4	17
106	BRAF V600E mutation in neocortical posterior temporal epileptogenic gangliogliomas. Journal of Clinical Neuroscience, 2015, 22, 1250-1253.	0.8	16
107	<i>TERT</i> Promoter Mutations in Papillary Thyroid Microcarcinomas. Thyroid, 2015, 25, 1013-1019.	2.4	86
108	A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encoded mitochondrial complex I genes in oncocytic thyroid tumors. BMC Cancer, 2015, 15, 157.	1.1	34

#	Article	IF	CITATIONS
109	BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. Modern Pathology, 2015, 28, 1343-1359.	2.9	47
110	Contribution of microRNA analysis to characterisation of pancreatic lesions: a review. Journal of Clinical Pathology, 2015, 68, 859-869.	1.0	16
111	Post progression survival in glioblastoma: where are we?. Journal of Neuro-Oncology, 2015, 121, 399-404.	1.4	10
112	Association Between <i>BRAF</i> V600E Mutation and Recurrence of Papillary Thyroid Cancer. Journal of Clinical Oncology, 2015, 33, 42-50.	0.8	448
113	High-resolution genomic profiling of thyroid lesions uncovers preferential copy number gains affecting mitochondrial biogenesis loci in the oncocytic variants. American Journal of Cancer Research, 2015, 5, 1954-71.	1.4	6
114	Next Generation Sequencing Improves the Accuracy of KRAS Mutation Analysis in Endoscopic Ultrasound Fine Needle Aspiration Pancreatic Lesions. PLoS ONE, 2014, 9, e87651.	1.1	68
115	Molecular diagnosis of carcinomas of the thyroid gland. Frontiers in Bioscience - Elite, 2014, E6, 1-14.	0.9	6
116	High-Sensitivity <i>BRAF</i> Mutation Analysis: <i>BRAF</i> V600E Is Acquired Early During Tumor Development but Is Heterogeneously Distributed in a Subset of Papillary Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1530-E1538.	1.8	64
117	Anoctamin 1 is Apically Expressed on Thyroid Follicular Cells and Contributes to ATP- and Calcium-Activated Iodide Efflux. Cellular Physiology and Biochemistry, 2014, 34, 966-980.	1.1	28
118	Mutant <i> <scp>BRAF</scp> </i> in lowâ€grade epilepsyâ€associated tumors and focal cortical dysplasia. Annals of Clinical and Translational Neurology, 2014, 1, 130-134.	1.7	33
119	Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E832-E840.	1.8	73
120	Deep sequencing of KIT, MET, PIK3CA, and PTEN hotspots in papillary thyroid carcinomas with distant metastases. Endocrine-Related Cancer, 2014, 21, L23-L26.	1.6	9
121	Tensegrity model hypothesis: may this paradigm be useful to explain hepatic and pancreatic carcinogenesis in patients with persistent hepatitis B or hepatitis C virus infection?. JOP: Journal of the Pancreas, 2014, 15, 151-64.	1.5	8
122	Tall Cell Variant of Papillary Thyroid Microcarcinoma: Clinicopathologic Features with <i>BRAF</i> ^{V600E} Mutational Analysis. Thyroid, 2013, 23, 1525-1531.	2.4	44
123	Papillary thyroid microcarcinoma associated with metastasis and fatal outcome: is the microcarcinoma an incidental finding?—reply. Human Pathology, 2013, 44, 1962-1963.	1.1	2
124	Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations. Endocrine, 2013, 43, 147-153.	1.1	13
125	Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases. Human Pathology, 2013, 44, 556-565.	1.1	40
126	Where Birt–Hogg–Dubé meets Cowden Syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours. European Journal of Human Genetics, 2013, 21, 1169-1172.	1.4	23

#	Article	IF	CITATIONS
127	Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas. Human Molecular Genetics, 2013, 22, 226-238.	1.4	55
128	Multiple <i>KRAS</i> Mutations in Pancreatic Adenocarcinoma. International Journal of Surgical Pathology, 2013, 21, 546-552.	0.4	22
129	454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. OncoTargets and Therapy, 2013, 6, 1057.	1.0	36
130	Pancreatic carcinoma development: new etiological and pathogenetic evidence. Italian Journal of Medicine, 2013, 7, 242.	0.2	1
131	Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy). PLoS ONE, 2013, 8, e83607.	1.1	76
132	Simultaneous Occurrence of PAX8-PPARg and RET-PTC3 Rearrangements in a Follicular Variant of Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2012, 36, 1415-1420.	2.1	6
133	Allele Specific Locked Nucleic Acid Quantitative PCR (ASLNAqPCR): An Accurate and Cost-Effective Assay to Diagnose and Quantify KRAS and BRAF Mutation. PLoS ONE, 2012, 7, e36084.	1.1	55
134	T[20] repeat in the 3′-untranslated region of the MT1X gene: a marker with high sensitivity and specificity to detect microsatellite instability in colorectal cancer. International Journal of Colorectal Disease, 2012, 27, 647-656.	1.0	20
135	Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology. Breast Cancer Research and Treatment, 2012, 132, 15-28.	1.1	19
136	Oncocytic carcinoma of the breast: frequency, morphology and follow-up. Human Pathology, 2011, 42, 166-175.	1.1	30
137	Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors. Oncology Reports, 2011, 26, 1075-80.	1.2	8
138	Poorly Differentiated Thyroid Carcinoma. Are We There Yet?. Endocrine Pathology, 2011, 22, 190-194.	5.2	41
139	BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. European Journal of Endocrinology, 2011, 165, 455-463.	1.9	25
140	Fine-Needle Aspiration and Intraoperative Consultation in Thyroid Pathology: When and How?. International Journal of Surgical Pathology, 2011, 19, 141-144.	0.4	15
141	Thyroid gland. , 2011, , 487-564.		59
142	Encapsulated Well-differentiated Follicular-patterned Thyroid Carcinomas Do Not Play a Significant Role in the Fatality Rates From Thyroid Carcinoma. American Journal of Surgical Pathology, 2010, 34, 868-872.	2.1	124
143	In Response:. American Journal of Surgical Pathology, 2010, 34, 1560.	2.1	1
144	Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference. BMC Cancer, 2010, 10, 48.	1.1	33

#	Article	IF	CITATIONS
145	Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies. Journal of Oncology, 2010, 2010, 1-7.	0.6	57
146	Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Annals of Oncology, 2010, 21, 562-567.	0.6	70
147	Novel gene rearrangements in transformed breast cells identified by high-resolution breakpoint analysis of chromosomal aberrations. Endocrine-Related Cancer, 2010, 17, 87-98.	1.6	33
148	The genetic and metabolic signature of oncocytic transformation implicates HIF1α destabilization. Human Molecular Genetics, 2010, 19, 1019-1032.	1.4	113
149	Molecular features of thyroid oncocytic tumors. Molecular and Cellular Endocrinology, 2010, 321, 67-76.	1.6	39
150	RET/PTC Rearrangement Occurring in Primary Peritoneal Carcinoma. International Journal of Surgical Pathology, 2009, 17, 187-197.	0.4	15
151	Sarcomas. , 2009, , 119-130.		0
152	Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. British Journal of Cancer, 2008, 99, 83-89.	2.9	167
153	<i>MGMT</i> Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients. Journal of Clinical Oncology, 2008, 26, 2192-2197.	0.8	760
154	Trisomy 17 as a Marker for a Subset of Noninvasive Thyroid Nodules with Focal Features of Papillary Carcinoma: Cytogenetic and Molecular Analysis of 62 Cases and Correlation with Histological Findings. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 177-181.	1.8	16
155	Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9001-9006.	3.3	256
156	Tall Cell Variant of Papillary Thyroid Carcinoma without Extrathyroid Extension: Biologic Behavior and Clinical Implications. Thyroid, 2007, 17, 655-661.	2.4	119
157	Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). British Journal of Cancer, 2007, 96, 1047-1051.	2.9	179
158	Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer. Clinical Cancer Research, 2007, 13, 1161-1170.	3.2	362
159	Malignant Ectomesenchymoma: Genetic Profile Reflects Rhabdomyosarcomatous Differentiation. Diagnostic Molecular Pathology, 2007, 16, 243-248.	2.1	19
160	Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene, 2007, 26, 7590-7595.	2.6	373
161	Monitoring HCV RNA viral load by locked nucleic acid molecular beacons real time PCR. Journal of Virological Methods, 2007, 140, 148-154.	1.0	19

#	Article	IF	CITATIONS
163	RET/Papillary Thyroid Cancer Rearrangement in Nonneoplastic Thyrocytes: Follicular Cells of Hashimoto's Thyroiditis Share Low-Level Recombination Events with a Subset of Papillary Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2414-2423.	1.8	175
164	Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC). Reviews on Recent Clinical Trials, 2006, 1, 1-13.	0.4	44
165	Clinical experience with gefitinib: An update. Critical Reviews in Oncology/Hematology, 2006, 58, 31-45.	2.0	50
166	Follicular variant of papillary thyroid carcinoma. Cancer, 2006, 107, 1255-1264.	2.0	363
167	Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. International Journal of Cancer, 2006, 119, 2322-2329.	2.3	162
168	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2006, 17, 1120-1127.	0.6	93
169	Defective Oxidative Phosphorylation in Thyroid Oncocytic Carcinoma Is Associated with Pathogenic Mitochondrial DNA Mutations Affecting Complexes I and III. Cancer Research, 2006, 66, 6087-6096.	0.4	204
170	Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. British Journal of Cancer, 2006, 95, 1529-1536.	2.9	53
171	HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumor. Modern Pathology, 2005, 18, 1519-1526.	2.9	14
172	Tumor-specific changes in mtDNA content in human cancer. International Journal of Cancer, 2005, 116, 920-924.	2.3	160
173	BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6373-6379.	1.8	893
174	Assessment of RET/PTC Oncogene Activation in Thyroid Nodules Utilizing Laser Microdissection Followed by Nested RT-PCR. , 2005, 293, 103-112.		4
175	Diet and Nutrient Intakes and Risk of Non-Hodgkin's Lymphoma in Connecticut Women. American Journal of Epidemiology, 2004, 159, 454-466.	1.6	102
176	Blood Transfusion and Risk of Non-Hodgkin's Lymphoma in Connecticut Women. American Journal of Epidemiology, 2004, 160, 325-330.	1.6	30
177	Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis. Cancer Research, 2004, 64, 1664-1668.	0.4	142
178	Menstrual and Reproductive Factors and Risk of Non-Hodgkin's Lymphoma among Connecticut Women. American Journal of Epidemiology, 2004, 160, 766-773.	1.6	34
179	Hair-coloring Product Use and Risk of Non-Hodgkin's Lymphoma: A Population-based Case-Control Study in Connecticut. American Journal of Epidemiology, 2004, 159, 148-154.	1.6	98
180	Genome-Wide Profiling of Papillary Thyroid Cancer Identifies MUC1 as an Independent Prognostic Marker. Cancer Research, 2004, 64, 3780-3789.	0.4	137

#	Article	IF	CITATIONS
181	BRAF T1796A Transversion Mutation in Various Thyroid Neoplasms. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1365-1368.	1.8	125
182	Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Laboratory Investigation, 2004, 84, 1557-1570.	1.7	54
183	Prior Medical Conditions and Medication use and Risk of non-Hodgkin lymphoma in Connecticut United States Women. Cancer Causes and Control, 2004, 15, 419-428.	0.8	141
184	Three-dimensional reconstruction of vessel distribution in benign and malignant lesions of thyroid. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 189-98.	1.4	20
185	The Oncogenic Activity of RET Point Mutants for Follicular Thyroid Cells May Account for the Occurrence of Papillary Thyroid Carcinoma in Patients Affected by Familial Medullary Thyroid Carcinoma. American Journal of Pathology, 2004, 165, 511-521.	1.9	35
186	Differential Expression of HMGA1 and HMGA2 in Dermatofibroma and Dermatofibrosarcoma Protuberans: Potential Diagnostic Applications, and Comparison with Histologic Findings, CD34, and Factor XIIIa Immunoreactivity. American Journal of Dermatopathology, 2004, 26, 267-272.	0.3	49
187	Nuclear Alterations and RET/PTC Activation. American Journal of Surgical Pathology, 2004, 28, 974-975.	2.1	15
188	Alcohol use and risk of non-Hodgkin's lymphoma among Connecticut women (United States). Cancer Causes and Control, 2003, 14, 687-694.	0.8	43
189	Aneuploidy in oncocytic lesions of the thyroid gland: Diffuse accumulation of mitochondria within the cell is associated with trisomy 7 and progressive numerical chromosomal alterations. Genes Chromosomes and Cancer, 2003, 38, 22-31.	1.5	53
190	Cigarette smoking and risk of non-Hodgkin lymphoma subtypes among women. British Journal of Cancer, 2003, 89, 2087-2092.	2.9	46
191	Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene, 2003, 22, 246-255.	2.6	46
192	ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer. Journal of Clinical Oncology, 2003, 21, 3226-3235.	0.8	348
193	Real-time Quantitative RT-PCR of Cyclin D1 mRNA in Mantle Cell Lymphoma: Comparison with FISH and Immunohistochemistry. Leukemia and Lymphoma, 2003, 44, 1385-1394.	0.6	36
194	RASPoint Mutations and PAX8-PPARÎ ³ Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2318-2326.	1.8	664
195	Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-α-induced Apoptosis via the AKT/Survivin Pathway. Journal of Biological Chemistry, 2003, 278, 50402-50411.	1.6	133
196	Systemic <i>Tropheryma whippleii</i> Infection Associated With Monoclonal B-Cell Proliferation: A <i>Helicobacter pylori</i> –Type Pathogenesis?. Archives of Pathology and Laboratory Medicine, 2003, 127, 1619-1622.	1.2	11
197	Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Research, 2003, 63, 2316-21.	0.4	107
198	RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 370-379.	1.8	99

#	Article	IF	CITATIONS
199	Semireannealing, Single-Stranded Conformational Polymorphism: A Novel and Effective Tool for the Diagnosis of T-Cell Clonality. Diagnostic Molecular Pathology, 2002, 11, 67-74.	2.1	4
200	Assessment of RET/PTC Oncogene Activation and Clonality in Thyroid Nodules with Incomplete Morphological Evidence of Papillary Carcinoma. American Journal of Pathology, 2002, 160, 2157-2167.	1.9	139
201	Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Journal of Pathology, 2002, 196, 194-203.	2.1	131
202	Molecular Pathobiology of Thyroid Neoplasms. Endocrine Pathology, 2002, 13, 271-288.	5.2	67
203	β-Catenin Dysregulation in Thyroid Neoplasms. American Journal of Pathology, 2001, 158, 987-996.	1.9	264
204	RET Oncogene Activation in Papillary Thyroid Carcinoma. Advances in Anatomic Pathology, 2001, 8, 345-354.	2.4	205
205	Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type. Cancer, 2001, 92, 2273-2279.	2.0	53
206	Chromosomal translocation t(8;12) induces aberrantHMGIC expression in aggressive angiomyxoma of the vulva. Genes Chromosomes and Cancer, 2001, 32, 172-176.	1.5	109
207	The Tumor-Associated Gene HMGIC Is Expressed in Normal and Osteoarthritis-Affected Synovia. Modern Pathology, 2001, 14, 311-317.	2.9	13
208	Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. , 2000, 190, 31-38.		141
209	Coordinated expression and amplification of theMDM2,CDK4, andHMGI-C genes in atypical lipomatous tumours. , 2000, 190, 531-536.		250
210	Dysregulation ofHMGIC in a uterine lipoleiomyoma with a complex rearrangement including chromosomes 7, 12, and 14. , 2000, 27, 209-215.		28
211	Cytogenetic evidence of clonality in cutaneous benign fibrous histiocytomas: a report of the CHAMP Study Group. Histopathology, 2000, 37, 212-217.	1.6	60
212	HMGI-C and HMGI(Y) Immunoreactivity Correlates with Cytogenetic Abnormalities in Lipomas, Pulmonary Chondroid Hamartomas, Endometrial Polyps, and Uterine Leiomyomas and is Compatible with Rearrangement of the HMGI-C and HMGI(Y) Genes. Laboratory Investigation, 2000, 80, 359-369.	1.7	135
213	Recurrent chromosome aberrations in fibrous dysplasia of the bone. Cancer Genetics and Cytogenetics, 2000, 122, 30-32.	1.0	44
214	Comparative Cytogenetic Study of Spindle Cell and Pleomorphic Leiomyosarcomas of Soft Tissues. Cancer Genetics and Cytogenetics, 2000, 116, 66-73.	1.0	60
215	Cytogenetics of Thyroid Nodules in Hashimoto Thyroiditis. Cancer Genetics and Cytogenetics, 2000, 120, 87-88.	1.0	10
216	Cytogenetic-Morphologic Correlations in Aneurysmal Bone Cyst, Giant Cell Tumor of Bone and Combined Lesions. A Report from the CHAMP Study Group. Modern Pathology, 2000, 13, 1206-1210.	2.9	101

#	Article	IF	CITATIONS
217	Cytogenetic, Clinical, and Morphologic Correlations in 78 Cases of Fibromatosis: A Report from the CHAMP Study Group. Modern Pathology, 2000, 13, 1080-1085.	2.9	99
218	Substrate Specificity of αvβ3Integrin-mediated Cell Migration and Phosphatidylinositol 3-Kinase/AKT Pathway Activation. Journal of Biological Chemistry, 2000, 275, 24565-24574.	1.6	136
219	Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. , 2000, 190, 531.		4
220	Epstein-Barr Virus RNA Detection and Glandular Differentiation in Nasopharyngeal Carcinoma. Archives of Pathology and Laboratory Medicine, 2000, 124, 1369-1372.	1.2	4
221	Correlation between Clinicopathological Features and Karyotype in Spindle Cell Sarcomas. American Journal of Pathology, 1999, 154, 1841-1847.	1.9	109
222	HMGI(Y) and HMGI-C Dysregulation. Advances in Anatomic Pathology, 1999, 6, 237-246.	2.4	116
223	Downregulation of p27KIP1 and Ki67/Mib1 Labeling Index Support the Classification of Thyroid Carcinoma Into Prognostically Relevant Categories. American Journal of Surgical Pathology, 1999, 23, 678-685.	2.1	124
224	Biliary Tract Obstruction Secondary to Mycosis Fungoides: A Case Report. Journal of Clinical Gastroenterology, 1999, 28, 56-60.	1.1	7
225	p27kip1 acts as a downstream effector of and is coexpressed with the β1C integrin in prostatic adenocarcinoma. Journal of Clinical Investigation, 1999, 103, 321-329.	3.9	47
226	Comparison of Chromosomal Patterns with Clinical Features in 165 Lipomas: A Report of the CHAMP Study Group. Cancer Genetics and Cytogenetics, 1998, 102, 46-49.	1.0	60
227	Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: A report of the CHAMP study group. , 1998, 22, 16-25.		161
228	Amplification and expression of theHMGIC gene in a benign endometrial polyp. Genes Chromosomes and Cancer, 1998, 22, 95-99.	1.5	35
229	Oncocytic tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1998, 433, 5-12.	1.4	148
230	Composed designs. Journal of Statistical Planning and Inference, 1998, 73, 331-351.	0.4	0
231	β1C Integrin in Epithelial Cells Correlates with a Nonproliferative Phenotype. American Journal of Pathology, 1998, 153, 1079-1087.	1.9	45
232	Morphologic, Immunophenotypic, and Molecular Evaluation of Bone Marrow Involvement in Non-Hodgkin's Lymphoma. Diagnostic Molecular Pathology, 1998, 7, 90-95.	2.1	33
233	Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease Journal of Clinical Oncology, 1998, 16, 1158-1166.	0.8	79
234	Histologic and Immunophenotypic Features Prior to Transformation in Patients with Transformed Cutaneous T-Cell Lymphoma. American Journal of Dermatopathology, 1998, 20, 1-6.	0.3	30

#	Article	IF	CITATIONS
235	Modulation of cell proliferation by the integrin cytoplasmic domain. Kidney International, 1997, 51, 1434-1440.	2.6	8
236	Undifferentiated rhabdomyosarcoma with lymphoid phenotype expression. , 1997, 28, 165-170.		14
237	Cytogenetic Analysis of Subcutaneous Angiolipoma: Further Evidence Supporting Its Difference from Ordinary Pure Lipomas. American Journal of Surgical Pathology, 1997, 21, 441-444.	2.1	86
238	Depletion of stromal and intraepithelial antigen-presenting cells in cervical neoplasia in human immunodeficiency virus infection. Human Pathology, 1996, 27, 834-838.	1.1	36
239	Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases Journal of Clinical Oncology, 1996, 14, 1943-1949.	0.8	368
240	Burkitt's Lymphoma-Leukemia in Patients Treated for Hodgkin's Disease. Cancer Investigation, 1996, 14, 527-533.	0.6	7
241	Malignant mesenchymoma. , 1996, 77, 467-473.		41
242	Duplication of chromosome segment 12q15-24 is associated with atypical lipomatous tumors. A report of the CHAMP collaborative study group. , 1996, 67, 632-635.		34
243	Lymphomatoid granulomatosis of the skin and lung. An angiocentric T-cell-rich B-cell lymphoproliferative disorder. Archives of Dermatology, 1996, 132, 1464-1470.	1.7	41
244	Combined Morphologic and Karyotypic Study of 28 Myxoid Liposarcomas. American Journal of Surgical Pathology, 1996, 20, 1047-1055.	2.1	107
245	Combined Morphologic and Karyotypic Study of 59 Atypical Lipomatous Tumors. American Journal of Surgical Pathology, 1996, 20, 1182-1189.	2.1	200
246	Analysis of nuclear and mitochondrial DNA alterations in thyroid and renal oncocytic tumors. Cytogenetic and Genome Research, 1994, 66, 253-259.	0.6	79
247	Asymptotic questions in Galois geometries. Discrete Mathematics, 1994, 129, 191-203.	0.4	1
248	Metastatic dermatofibrosarcoma protuberans with fibrosarcomatous change in the absence of local recurrence. A case report of simultaneous occurrence with a malignant giant cell tumor of soft parts. Cancer, 1993, 72, 462-468.	2.0	26
249	Autoantibodies to a 128-kd Synaptic Protein in Three Women with the Stiff-Man Syndrome and Breast Cancer. New England Journal of Medicine, 1993, 328, 546-551.	13.9	327
250	Diagnosis of Gastrointestinal T-Cell Lymphomas in Routinely Processed Tissues. Journal of Clinical Gastroenterology, 1993, 17, 57-66.	1.1	11
251	Divergent Myosarcomatous Differentiation in Retroperitoneal Liposarcoma. American Journal of Surgical Pathology, 1993, 17, 546-556.	2.1	72
252	Epithelioid Angiosarcoma Arising in Uterine Leiomyomas. American Journal of Clinical Pathology, 1993, 100, 514-518.	0.4	50

#	Article	IF	CITATIONS
253	Eliminating mitochondrial DNA competition for nuclear DNA primers Genome Research, 1993, 3, 39-45.	2.4	4
254	Oncocytic Neoplasms of the Thyroid Gland. Pathology International, 1992, 42, 305-315.	0.6	25
255	Prenatal diagnosis of a fetus with terminal deletion of chromosome 1 (q41). Prenatal Diagnosis, 1991, 11, 867-873.	1.1	17
256	Comparative study by S-100 and GFAP immunohistochemistry of glial cell populations in the early stages of human spinal cord development. Developmental Brain Research, 1987, 37, 251-255.	2.1	23
257	Protein absorption by tubular mesonephric and metanephric structures in the human embryo. Cell and Tissue Research, 1986, 246, 77-80.	1.5	6
258	Detection by S-100 immunolabelling of interdigitating reticulum cells in human thymomas. Vigiliae Christianae, 1984, 45, 187-195.	0.1	40
259	S-100 antigen labels neoplastic cells in liposarcoma and cartilaginous tumours. Virchows Archiv A, Pathological Anatomy and Histology, 1983, 402, 139-145.	1.3	48
260	BRAFV600E status and Stimulated Thyroglobulin at ablation time increase prognostic value of American Thyroid Association (ATA) classification systems for persistent disease in Differentiated Thyroid Carcinoma (DTC). Endocrine Abstracts, 0, , .	0.0	1
261	Multifocal Fibrosing Thyroiditis: an Under-recognized Mimicker of Papillary Thyroid Carcinoma. Endocrine Pathology, 0, , .	5.2	1